Para IV Winners and Losers - July 2018
This month’s Para IV developments suggest that there is likely to be benefit to Par Pharma, Dr. Reddy'S Laboratories (DRRD IN) & Amneal...
293 Views
India: After Maruti Suzuki and Reliance Industries, Will Larsen & Toubro Outperform the Markets Now?
It has been a struggle to find money making ideas in Indian large cap spaceIndian markets have done well in CY17 with BSE SENSEX delivering...
195 Views
GEM Fund Positioning: Indian Healthcare - Condition Worsening
We analyse the stock allocations of 124 global emerging market equity long only funds from 2011 to today. All Funds are actively managed and the...
199 Views
A Storm Will Follow the Lull
Newsflow around the US and state governments' antitrust investigations of the generic drug industry has been quiet since mid-December. Some lull is...
724 Views
Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
AML represents one of the largest hematologic cancer populations with one of the worst survival rates. Global prevalence is expected to increase at...
522 Views